Analytical Data
-
Gene name
HLA-A*02:01&B2M&KRAS WT(KLVVVGAGGV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & KRAS (KLVVVGAGGV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KLVVVGAGGV
-
Molecular Weight
40-45 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is one of the most prevalent major histocompatibility complex (MHC) class I molecules in the human population, playing a critical role in the presentation of antigens to CD8+ T cells, which is essential for initiating immune responses against tumors and infections. The study of HLA-A*02:01 in conjunction with beta-2-microglobulin (B2M) is vital, as B2M is essential for the stability and surface expression of MHC class I molecules, thus influencing T cell recognition. The KRAS gene is frequently mutated in various cancers, leading to active RAS protein and consequent malignant transformation. In particular, the wild-type (WT) KRAS peptide KLVVVGAGGV has been identified as a potential target for T cell-based immunotherapy in KRAS-driven tumors. By investigating the recombinant monomer of HLA-A*02:01, B2M, and KRAS WT peptide, researchers aim to enhance our understanding of T cell receptor (TCR) interactions and the underlying mechanisms of immune recognition. This knowledge is crucial for the development of therapeutic strategies, including cancer vaccines and adoptive T cell therapies, to effectively target tumors expressing KRAS WT peptides, ultimately improving clinical outcomes for patients with solid tumors. Understanding the structural and functional dynamics of this complex can lead to innovative approaches in cancer immunotherapy, maximizing the efficacy of anti-tumor immune responses.
